Effects of Shizhifang on NLRP3 Inflammasome Activation and Renal Tubular Injury in Hyperuricemic Rats

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td class="align_left">Group</td><td class="align_center"><span style="width: 11.0475ptpx;"><svg height="8.8423pt" id="M20" style="vertical-align:-0.2064009pt" version="1.1" viewbox="-0.0498162 -8.6359 11.0475 8.8423" width="11.0475pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M822 650H589L583 622C660 617 677 607 674 561C672 534 664 481 647 390L600 137H596L273 650H126L120 622C176 620 194 615 207 594C221 571 225 557 214 504L161 257C141 166 129 112 121 85C108 42 83 30 29 28L23 0H260L266 28C193 33 173 42 176 89C178 122 186 172 202 255L256 527H259L583 -8H612L690 390C708 481 720 535 728 558C744 603 756 619 816 622L822 650Z" id="g113-79"></path></g></svg></span></td><td class="align_center">Urine volume (L/24 h)</td><td class="align_center">Uua (<i>μ</i>mol/L)</td><td class="align_center">Uua (<i>μ</i>moL/24 h)</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td class="align_left">Control</td><td class="align_center">7</td><td class="align_center">0.036 ± 0.01</td><td class="align_center">1969.34 ± 808.21</td><td class="align_center">64.00 ± 20.7<svg height="10.2359pt" id="M21" style="vertical-align:-0.2063999pt" version="1.1" viewbox="-0.0498162 -10.0295 12.707 10.2359" width="12.707pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M249 635C141 635 70 555 70 471C70 401 114 353 179 316C143 294 106 267 90 252C68 231 45 202 45 157C45 50 130 -12 237 -12C322 -12 435 52 435 169C435 256 372 304 303 343C349 374 375 398 383 407C401 429 411 458 411 487C411 569 344 635 249 635ZM238 603C285 603 337 567 337 482C337 422 310 385 276 358C205 393 145 426 145 500C145 552 179 603 238 603ZM248 20C183 20 125 70 125 163C125 218 158 268 206 300C284 261 355 217 355 143C355 66 308 20 248 20Z" id="g113-57"></path></g><g transform="matrix(.0091,0,0,-0.0091,6.24,-5.741)"><path d="M499 152C501 180 492 209 480 228C432 233 403 235 357 256C403 278 432 279 480 284C492 303 504 328 499 359C477 375 447 382 424 380C396 342 380 317 338 288C342 339 356 364 376 408C366 429 350 451 320 463C295 451 274 429 265 408C284 364 297 339 301 288C259 317 244 341 216 380C193 382 166 379 141 359C139 332 148 303 160 284C208 279 237 277 283 256C237 234 208 233 160 228C148 209 136 184 141 152C163 137 193 130 216 132C244 170 260 195 302 224C298 173 284 148 265 104C274 83 290 61 320 49C345 61 366 83 376 104C356 148 343 173 339 224C381 195 396 171 424 132C447 130 474 133 499 152Z" id="g14-43"></path></g></svg></td></tr><tr><td class="align_left">OA</td><td class="align_center">7</td><td class="align_center">0.034 ± 0.01</td><td class="align_center">4271.16 ± 2429.5</td><td class="align_center">124.39 ± 29.39</td></tr><tr><td class="align_left">OA + Allopurinol</td><td class="align_center">7</td><td class="align_center">0.051 ± 0.00</td><td class="align_center">4102.0 ± 1576.09</td><td class="align_center">211.91 ± 88.6<svg height="11.7339pt" id="M22" style="vertical-align:-0.2063999pt" version="1.1" viewbox="-0.0498162 -11.5275 17.1553 11.7339" width="17.1553pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M244 635C114 635 38 519 38 422C38 317 111 240 217 240C236 240 255 244 277 256L345 292C311 140 203 39 59 15L64 -15C89 -15 150 -5 204 17C339 72 440 202 440 386C440 521 368 635 244 635ZM228 602C326 602 352 479 352 390C352 370 351 347 348 324C327 308 293 296 258 296C174 296 124 369 124 458C124 517 152 602 228 602Z" id="g113-58"></path></g><g transform="matrix(.0091,0,0,-0.0091,6.241,-5.741)"><path d="M499 152C501 180 492 209 480 228C432 233 403 235 357 256C403 278 432 279 480 284C492 303 504 328 499 359C477 375 447 382 424 380C396 342 380 317 338 288C342 339 356 364 376 408C366 429 350 451 320 463C295 451 274 429 265 408C284 364 297 339 301 288C259 317 244 341 216 380C193 382 166 379 141 359C139 332 148 303 160 284C208 279 237 277 283 256C237 234 208 233 160 228C148 209 136 184 141 152C163 137 193 130 216 132C244 170 260 195 302 224C298 173 284 148 265 104C274 83 290 61 320 49C345 61 366 83 376 104C356 148 343 173 339 224C381 195 396 171 424 132C447 130 474 133 499 152Z" id="g14-43"></path></g><g transform="matrix(.0091,0,0,-0.0091,12.087,-5.741)"><path d="M457 455H370L403 612H360L326 455H218L252 612H210L175 455H77L68 394H161L132 257H31L20 196H117L77 19H120L159 196H268L230 19H272L311 196H402L412 257H325L355 394H447L457 455ZM313 394L283 257H175L204 394H313Z" id="g58-33"></path></g></svg></td></tr><tr><td class="align_left">OA + SZF</td><td class="align_center">7</td><td class="align_center">0.045 ± 0.02</td><td class="align_center">5254.3 ± 3916.99</td><td class="align_center">186.51 ± 24.7<svg height="10.0793pt" id="M23" style="vertical-align:-0.04979992pt" version="1.1" viewbox="-0.0498162 -10.0295 12.707 10.0793" width="12.707pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M412 140C382 77 369 73 315 73H129L270 222C362 320 402 379 402 466C402 571 322 635 234 635C177 635 130 609 99 576L42 495L64 475C90 514 133 568 201 568C274 568 318 519 318 435C318 349 255 267 193 193C144 135 87 78 32 23V0H405C417 45 427 89 440 131L412 140Z" id="g113-51"></path></g><g transform="matrix(.0091,0,0,-0.0091,6.24,-5.741)"><path d="M499 152C501 180 492 209 480 228C432 233 403 235 357 256C403 278 432 279 480 284C492 303 504 328 499 359C477 375 447 382 424 380C396 342 380 317 338 288C342 339 356 364 376 408C366 429 350 451 320 463C295 451 274 429 265 408C284 364 297 339 301 288C259 317 244 341 216 380C193 382 166 379 141 359C139 332 148 303 160 284C208 279 237 277 283 256C237 234 208 233 160 228C148 209 136 184 141 152C163 137 193 130 216 132C244 170 260 195 302 224C298 173 284 148 265 104C274 83 290 61 320 49C345 61 366 83 376 104C356 148 343 173 339 224C381 195 396 171 424 132C447 130 474 133 499 152Z" id="g14-43"></path></g></svg></td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><svg height="13.9365pt" id="M24" style="vertical-align:-3.834pt" version="1.1" viewbox="-0.0498162 -10.1025 50.9184 13.9365" width="50.9184pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M486 158C486 177 478 202 466 220C413 228 386 236 336 262C386 288 413 297 466 304C478 323 486 347 485 366C470 376 444 381 422 380C389 338 368 319 321 288C323 345 329 372 349 422C339 442 322 461 305 470C289 461 271 442 262 422C281 372 287 345 290 288C243 319 222 338 189 380C167 381 142 376 125 366C125 347 133 322 145 304C198 296 225 288 275 262C225 236 198 227 145 220C133 201 125 177 126 158C141 148 167 143 189 144C222 186 243 205 290 236C288 179 282 152 262 102C272 82 289 63 306 54C322 63 340 82 350 102C330 152 324 179 321 236C368 205 390 186 422 144C444 143 470 148 486 158Z" id="g50-43"></path></g><g transform="matrix(.013,0,0,-0.013,6.079,.966)"><path d="M600 480C600 590 528 650 384 650H143L137 622C222 614 225 607 210 531L130 127C113 41 106 36 23 28L17 0H294L300 28C204 36 195 42 212 127L243 284L314 263C327 263 339 263 352 264C465 271 600 337 600 480ZM508 481C508 351 402 304 329 304C289 304 265 311 250 317L295 559C302 594 310 606 323 611C335 616 350 619 367 619C455 619 508 573 508 481Z" id="g113-81"></path></g><g transform="matrix(.013,0,0,-0.013,17.762,0)"><path d="M512 -3V55L134 254V256L512 456V514L75 281V230L512 -3Z" id="g117-91"></path></g><g transform="matrix(.013,0,0,-0.013,29.025,0)"><path d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z" id="g113-49"></path></g><g transform="matrix(.013,0,0,-0.013,35.265,0)"><path d="M113 -12C146 -12 170 11 170 46C170 78 146 103 114 103S58 78 58 46C58 11 82 -12 113 -12Z" id="g113-47"></path></g><g transform="matrix(.013,0,0,-0.013,38.229,0)"><path d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z" id="g113-49"></path></g><g transform="matrix(.013,0,0,-0.013,44.469,0)"><path d="M153 550H386L412 615L406 623H120L82 318C104 327 142 338 184 338C294 338 347 275 347 187C347 112 305 39 221 39C160 39 119 71 97 89C88 97 80 96 71 90C59 80 50 67 49 57C48 45 52 36 66 23C80 9 123 -12 169 -12C221 -11 288 15 342 59C403 109 431 165 431 225C431 308 366 395 238 395C212 395 165 379 127 364L153 550Z" id="g113-54"></path></g></svg> versus the OA group. <svg height="15.3614pt" id="M25" style="vertical-align:-3.833899pt" version="1.1" viewbox="-0.0498162 -11.5275 49.7858 15.3614" width="49.7858pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M457 455H370L403 612H360L326 455H218L252 612H210L175 455H77L68 394H161L132 257H31L20 196H117L77 19H120L159 196H268L230 19H272L311 196H402L412 257H325L355 394H447L457 455ZM313 394L283 257H175L204 394H313Z" id="g58-33"></path></g><g transform="matrix(.013,0,0,-0.013,4.946,0)"><path d="M600 480C600 590 528 650 384 650H143L137 622C222 614 225 607 210 531L130 127C113 41 106 36 23 28L17 0H294L300 28C204 36 195 42 212 127L243 284L314 263C327 263 339 263 352 264C465 271 600 337 600 480ZM508 481C508 351 402 304 329 304C289 304 265 311 250 317L295 559C302 594 310 606 323 611C335 616 350 619 367 619C455 619 508 573 508 481Z" id="g113-81"></path></g><g transform="matrix(.013,0,0,-0.013,16.604,0)"><path d="M512 230V281L75 514V456L453 256V254L75 55V-3L512 230Z" id="g117-92"></path></g><g transform="matrix(.013,0,0,-0.013,27.867,0)"><path d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z" id="g113-49"></path></g><g transform="matrix(.013,0,0,-0.013,34.107,0)"><path d="M113 -12C146 -12 170 11 170 46C170 78 146 103 114 103S58 78 58 46C58 11 82 -12 113 -12Z" id="g113-47"></path></g><g transform="matrix(.013,0,0,-0.013,37.071,0)"><path d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z" id="g113-49"></path></g><g transform="matrix(.013,0,0,-0.013,43.311,0)"><path d="M153 550H386L412 615L406 623H120L82 318C104 327 142 338 184 338C294 338 347 275 347 187C347 112 305 39 221 39C160 39 119 71 97 89C88 97 80 96 71 90C59 80 50 67 49 57C48 45 52 36 66 23C80 9 123 -12 169 -12C221 -11 288 15 342 59C403 109 431 165 431 225C431 308 366 395 238 395C212 395 165 379 127 364L153 550Z" id="g113-54"></path></g></svg> versus the OA + Allopurinol group.<br/></td></tr></table>

Total urine uric acid excretion in each group (mean ± SD).

Evidence-Based Complementary and Alternative Medicine

tab3

Table 3

Table 3: Effects of Shizhifang on NLRP3 Inflammasome Activation and Renal Tubular Injury in Hyperuricemic Rats 